Publicaciones en las que colabora con José Antonio García Salcedo (12)

2015

  1. Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis

    Journal of Controlled Release, Vol. 197, pp. 190-198

  2. Relationship between proinflammatory and antioxidant proteins with the severity of cardiovascular disease in type 2 diabetes mellitus

    International Journal of Molecular Sciences, Vol. 16, Núm. 5, pp. 9469-9483

  3. Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis

    PLoS Pathogens, Vol. 11, Núm. 6

2014

  1. Monovinyl sulfone B-cyclodextrin. a flexible drug carrier system

    ChemMedChem, Vol. 9, Núm. 2, pp. 383-389

  2. Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids

    Osteoporosis International, Vol. 25, Núm. 2, pp. 645-651

2013

  1. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels

    Diabetes Care, Vol. 36, Núm. 6, pp. 1667-1674

  2. Novel therapy based on camelid nanobodies

    Therapeutic Delivery, Vol. 4, Núm. 10, pp. 1321-1336

  3. Serum osteoprotegerin: Bone or cardiovascular marker in Type 2 diabetes males?

    Journal of Endocrinological Investigation, Vol. 36, Núm. 1, pp. 16-20

2012

  1. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus

    Journal of Clinical Endocrinology and Metabolism, Vol. 97, Núm. 1, pp. 234-241

  2. Relationship between serum levels of osteocalcin and atherosclerotic disease in type 2 diabetes

    Diabetes and Metabolism, Vol. 38, Núm. 1, pp. 76-81

2011

  1. Pentosidina: Un nuevo biomarcador de las complicaciones en la diabetes mellitus

    Medicina Clinica, Vol. 136, Núm. 7, pp. 298-302

2010

  1. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor κb in women with postmenopausal osteoporosis

    Menopause, Vol. 17, Núm. 1, pp. 140-144